Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04113616
Title	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Kartos Therapeutics, Inc.
Indications	acute myeloid leukemia
Therapies	KRT-232 Decitabine + KRT-232 Cytarabine + KRT-232
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| BEL \| AUS